Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

NOVANTRONE. mitoXANTRONE for injection concentrate
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Gene Expression & Signaling in the Immune System
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Studying both sexes: a guiding principle for biomedicine.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Gordon Research Conference on Ion Channels
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
A much-needed focus on progression in multiple sclerosis.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
45th European Brain and Behaviour Society Meeting
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.

Pages